Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ALLO Allogene Therapeutics	$1.22 -0.8%	$1.32	$0.86 ▼ $3.78	$269.04M	0.31	3.27 million shs	1.61 million shs
IOVA Iovance Biotherapeutics	$1.85 -6.6%	$2.41	$1.64 ▼ $12.51	$661.19M	0.86	8.95 million shs	9.06 million shs
NVAX Novavax	$6.31 -1.6%	$6.74	$5.01 ▼ $17.81	$1.04B	2.81	6.38 million shs	3.73 million shs
PCVX Vaxcyte	$33.25 +1.2%	$33.02	$27.66 ▼ $121.06	$4.24B	1.2	1.46 million shs	1.12 million shs

10 "Recession Proof" Stocks That Will Thrive in Any Market

Which stocks are likely to thrive in today's challenging market? Enter your email address and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ALLO Allogene Therapeutics	0.00%	-8.21%	+16.04%	-26.79%	-51.76%
IOVA Iovance Biotherapeutics	0.00%	-11.61%	+11.24%	-45.45%	-75.28%
NVAX Novavax	0.00%	-7.64%	-11.59%	-16.64%	-54.21%
PCVX Vaxcyte	0.00%	-4.89%	+1.01%	-55.47%	-56.14%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ALLO Allogene Therapeutics	3.5783 of 5 stars	4.5	3.0	0.0	1.5	3.3	0.6
IOVA Iovance Biotherapeutics	4.6026 of 5 stars	4.3	1.0	4.2	1.7	4.2	1.3
NVAX Novavax	4.3991 of 5 stars	3.1	2.0	4.7	1.3	0.8	3.1
PCVX Vaxcyte	2.985 of 5 stars	4.6	2.0	0.0	2.6	1.7	0.0

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ALLO Allogene Therapeutics	2.90	Moderate Buy	$8.44	592.17% Upside
IOVA Iovance Biotherapeutics	2.50	Moderate Buy	$12.22	560.66% Upside
NVAX Novavax	2.29	Hold	$17.00	169.41% Upside
PCVX Vaxcyte	3.10	Buy	$136.50	310.53% Upside

Current Analyst Ratings Breakdown

Latest IOVA, ALLO, NVAX, and PCVX Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
6/17/2025	NVAX Novavax	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Sell	$6.00
5/19/2025	NVAX Novavax	B. Riley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy
5/16/2025	IOVA Iovance Biotherapeutics	UBS Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Buy ➝ Neutral	$17.00 ➝ $2.00
5/15/2025	ALLO Allogene Therapeutics	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$8.00 ➝ $4.00
5/14/2025	ALLO Allogene Therapeutics	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Overweight ➝ Overweight	$9.00 ➝ $7.00
5/14/2025	ALLO Allogene Therapeutics	Truist Financial Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$14.00 ➝ $10.00
5/14/2025	ALLO Allogene Therapeutics	Royal Bank Of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Outperform	$10.00 ➝ $10.00
5/14/2025	ALLO Allogene Therapeutics	Oppenheimer Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Outperform ➝ Outperform	$10.00 ➝ $9.00
5/14/2025	ALLO Allogene Therapeutics	Robert W. Baird Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Outperform ➝ Outperform	$12.00 ➝ $9.00
5/14/2025	ALLO Allogene Therapeutics	Citizens Jmp Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Outperform ➝ Market Perform
5/12/2025	IOVA Iovance Biotherapeutics	The Goldman Sachs Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$16.00 ➝ $8.00

(Data available from 6/23/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ALLO Allogene Therapeutics	$20K	13,342.53	N/A	N/A	$2.01 per share	0.61
IOVA Iovance Biotherapeutics	$164.07M	3.77	N/A	N/A	$2.33 per share	0.79
NVAX Novavax	$682.16M	1.50	N/A	N/A	($3.89) per share	-1.62
PCVX Vaxcyte	N/A	N/A	N/A	N/A	$26.52 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ALLO Allogene Therapeutics	-$257.59M	-$1.23	N/A	N/A	N/A	N/A	-52.98%	-41.28%	8/6/2025 (Estimated)
IOVA Iovance Biotherapeutics	-$372.18M	-$1.24	N/A	N/A	N/A	-176.49%	-49.71%	-39.18%	8/6/2025 (Estimated)
NVAX Novavax	-$187.50M	$2.65	2.38	78.88	0.07	38.14%	-115.51%	29.99%	8/14/2025 (Estimated)
PCVX Vaxcyte	-$463.93M	-$3.99	N/A	N/A	N/A	N/A	-17.12%	-16.26%	8/5/2025 (Estimated)

Latest IOVA, ALLO, NVAX, and PCVX Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/14/2025	Q1 2025	PCVX Vaxcyte	-$1.02	-$1.04	-$0.02	-$1.04	N/A	N/A
5/13/2025	Q1 2025	ALLO Allogene Therapeutics	-$0.28	-$0.28	N/A	-$0.28	$0.00 million	N/A
5/8/2025	Q1 2025	IOVA Iovance Biotherapeutics	-$0.25	-$0.36	-$0.11	-$0.36	$83.40 million	$49.32 million
5/8/2025	Q1 2025	NVAX Novavax	$0.71	$2.93	+$2.22	$2.93	$204.08 million	$666.66 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ALLO Allogene Therapeutics	N/A	N/A	N/A	N/A	N/A
IOVA Iovance Biotherapeutics	N/A	N/A	N/A	N/A	N/A
NVAX Novavax	N/A	N/A	N/A	N/A	N/A
PCVX Vaxcyte	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ALLO Allogene Therapeutics	N/A	9.71	9.71
IOVA Iovance Biotherapeutics	N/A	4.18	3.64
NVAX Novavax	N/A	2.06	2.03
PCVX Vaxcyte	N/A	17.70	17.70

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ALLO Allogene Therapeutics	83.63%
IOVA Iovance Biotherapeutics	77.03%
NVAX Novavax	53.04%
PCVX Vaxcyte	96.78%

Insider Ownership

Company	Insider Ownership
ALLO Allogene Therapeutics	13.20%
IOVA Iovance Biotherapeutics	10.30%
NVAX Novavax	1.00%
PCVX Vaxcyte	3.10%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ALLO Allogene Therapeutics	310	218.73 million	189.86 million	Optionable
IOVA Iovance Biotherapeutics	500	333.93 million	299.54 million	Optionable
NVAX Novavax	1,990	161.97 million	160.35 million	Optionable
PCVX Vaxcyte	160	129.00 million	125.01 million	Optionable

IOVA, ALLO, NVAX, and PCVX Headlines

Recent News About These Companies

GAMMA Investing LLC Purchases 9,422 Shares of Vaxcyte, Inc. (NASDAQ:PCVX)

June 21 at 3:18 AM | marketbeat.com

Assenagon Asset Management S.A. Buys New Position in Vaxcyte, Inc. (NASDAQ:PCVX)

June 14, 2025 | marketbeat.com

Vaxcyte, Inc. (NASDAQ:PCVX) Shares Bought by Rhumbline Advisers

June 12, 2025 | marketbeat.com

Brokers Offer Predictions for Vaxcyte FY2026 Earnings

June 11, 2025 | marketbeat.com

Vaxcyte: Sentiment Is Pushing The Shares Down

June 10, 2025 | seekingalpha.com

Vaxcyte, Inc. (NASDAQ:PCVX) Given Consensus Rating of "Buy" by Analysts

June 5, 2025 | marketbeat.com

103,683 Shares in Vaxcyte, Inc. (NASDAQ:PCVX) Purchased by Universal Beteiligungs und Servicegesellschaft mbH

June 1, 2025 | marketbeat.com

California State Teachers Retirement System Has $8.60 Million Stock Position in Vaxcyte, Inc. (NASDAQ:PCVX)

June 1, 2025 | marketbeat.com

Vaxcyte (NASDAQ:PCVX) Stock Price Up 5.7% - Should You Buy?

May 30, 2025 | marketbeat.com

Here’s Why Vaxcyte (PCVX) Sold Off in Q1

May 27, 2025 | msn.com

UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Boosts Stock Position in Vaxcyte, Inc. (NASDAQ:PCVX)

May 27, 2025 | marketbeat.com

Toronto Dominion Bank Invests $900,000 in Vaxcyte, Inc. (NASDAQ:PCVX)

May 26, 2025 | marketbeat.com

Frazier Life Sciences Management L.P. Trims Stock Holdings in Vaxcyte, Inc. (NASDAQ:PCVX)

May 23, 2025 | marketbeat.com

Millennium Management LLC Sells 21,857 Shares of Vaxcyte, Inc. (NASDAQ:PCVX)

May 23, 2025 | marketbeat.com

Is Vaxcyte, Inc. (PCVX) The Best Stock That Will Bounce Back?

May 9, 2025 | insidermonkey.com

Vaxcyte Reports First Quarter 2025 Financial Results and Provides Business Update

May 7, 2025 | globenewswire.com

Vaxcyte appoints new independent director

May 3, 2025 | uk.investing.com

Vaxcyte Appoints Dr. Olivier Brandicourt to Board

May 1, 2025 | tipranks.com

Vaxcyte, Inc. Appoints Dr. Olivier Brandicourt to Board of Directors to Advance Vaccine Development

May 1, 2025 | quiverquant.com

Vaxcyte Appoints Dr. Olivier Brandicourt to Board of Directors

May 1, 2025 | globenewswire.com

Is Vaxcyte, Inc. (PCVX) the Best Oversold NASDAQ Stock to Buy Right Now?

April 29, 2025 | insidermonkey.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

IPO Momentum Returns: 3 Stocks Rising After CoreWeave’s Surge
By Dan Schmidt | June 20, 2025
View IPO Momentum Returns: 3 Stocks Rising After CoreWeave’s Surge
3 Defense Stocks That Will Profit From a Golden Dome
By Chris Markoch | May 30, 2025
View 3 Defense Stocks That Will Profit From a Golden Dome
Intel's Turnaround Strategy Shifts From Planning to Attack Mode
By Jeffrey Neal Johnson | June 20, 2025
View Intel's Turnaround Strategy Shifts From Planning to Attack Mode
Ouster Soars 27% as DoD Grants First 3D LiDAR Approval for Drones
By Leo Miller | June 14, 2025
View Ouster Soars 27% as DoD Grants First 3D LiDAR Approval for Drones
Dave & Buster’s: Short-Covering Rally Signals Big Upside for PLAY
By Thomas Hughes | June 11, 2025
View Dave & Buster’s: Short-Covering Rally Signals Big Upside for PLAY

IOVA, ALLO, NVAX, and PCVX Company Descriptions

Allogene Therapeutics NASDAQ:ALLO

$1.22 -0.01 (-0.81%)

Closing price 04:00 PM Eastern

Extended Trading

$1.26 +0.04 (+3.28%)

As of 07:00 PM Eastern

Allogene Therapeutics, Inc., a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer. It develops, manufactures, and commercializes UCART19, an allogeneic chimeric antigen receptor (CAR) T cell product candidate for the treatment of pediatric and adult patients with R/R CD19 positive B-cell acute lymphoblastic leukemia (ALL). The company also develops cemacabtagene ansegedleucel, an engineered allogeneic CAR T cell product candidate that targets CD19 for the treatment of large B-cell lymphoma; and is in Phase 1b clinical trial for the treatment of chronic lymphocytic leukemia. In addition, it is developing ALLO-715, an allogeneic CAR T cell product candidate that is in a Phase 1 clinical trial for treating R/R multiple myeloma; ALLO-605, an allogeneic CAR T cell product candidate that is in a Phase I clinical trial for the treatment of multiple myeloma; ALLO-647, an anti-CD52 monoclonal antibody; CD70 to treat renal cell cancer; ALLO-316, an allogeneic CAR T cell product candidate that is in Phase 1 clinical trial for the treatment of advanced or metastatic RCC; ALLO-329 for the treatment of certain autoimmune diseases; DLL3 for the treatment of small cell lung cancer and other aggressive neuroendocrine tumors; and Claudin 18.2 for the treatment of gastric and pancreatic cancer. The company has license and collaboration agreements with Pfizer Inc.; Servier; Cellectis S.A.; and Notch Therapeutics Inc. It also has a strategic collaboration agreement with The University of Texas MD Anderson Cancer Center for the preclinical and clinical investigation of allogeneic CAR T cell product candidates; and a strategic partnership with Foresight Diagnostics to develop MRD-based In-Vitro Diagnostic for use in ALPHA3. The company was incorporated in 2017 and is headquartered in South San Francisco, California.

Iovance Biotherapeutics NASDAQ:IOVA

$1.85 -0.13 (-6.57%)

Closing price 04:00 PM Eastern

Extended Trading

$1.94 +0.09 (+4.59%)

As of 07:59 PM Eastern

Iovance Biotherapeutics, Inc., a commercial-stage biotechnology company, develops and commercializes cell therapies using autologous tumor infiltrating lymphocyte for the treatment of metastatic melanoma and other solid tumor cancers in the United States. The company offers Amtagvi, a tumor-derived autologous T cell immunotherapy used to treat adult patients with unresectable or metastatic melanoma; and Proleukin, an interleukin-2 product for the treatment of patients with metastatic renal cell carcinoma. It also develops lifileucel in combination with pembrolizumab to treat frontline advanced melanoma patients; LN-145 for the treatment of non-small cell lung cancer (NSCLC) and solid tumor cancers; IOV-4001, which is in Phase 1/2 IOV-GM1-201 clinical trial, for the treatment of NSCLC; and lifileucel for gynecological cancers. The company has collaborations and licensing agreements with WuXi Advanced Therapies, Inc.; National Institutes of Health; the National Cancer Institute; H. Lee Moffitt Cancer Center; The University of Texas M.D. Anderson Cancer Center; Cellectis S.A.; Novartis Pharma AG; and Boehringer Ingelheim Biopharmaceuticals GmbH. The company was formerly known as Lion Biotechnologies, Inc. and changed its name to Iovance Biotherapeutics, Inc. in June 2017. Iovance Biotherapeutics, Inc. was incorporated in 2007 and is headquartered in San Carlos, California.

Novavax NASDAQ:NVAX

$6.31 -0.10 (-1.56%)

Closing price 04:00 PM Eastern

Extended Trading

$6.34 +0.03 (+0.48%)

As of 08:00 PM Eastern

Novavax, Inc., a biotechnology company, that promotes improved health by discovering, developing, and commercializing vaccines to protect against serious infectious diseases. It offers vaccine platform that combines a recombinant protein approach, nanoparticle technology, and its patented Matrix-M adjuvant to enhance the immune response. It focuses on urgent health challenges, which is evaluating vaccines for COVID-19, influenza, and COVID-19 influenza combination. The company is commercializing a COVID-19 vaccine, NVX-CoV2373 under the brand names of Nuvaxovid, Covovax, and Novavax COVID-19 Vaccine, adjuvanted for adult and adolescent populations as a primary series and for both homologous and heterologous booster indications. It is also developing R21/Matrix-M adjuvant malaria vaccine. Novavax, Inc. was incorporated in 1987 and is headquartered in Gaithersburg, Maryland.

Vaxcyte NASDAQ:PCVX

$33.25 +0.38 (+1.16%)

Closing price 04:00 PM Eastern

Extended Trading

$32.90 -0.35 (-1.07%)

As of 06:33 PM Eastern

Vaxcyte, Inc., a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine for the prevention of invasive pneumococcal disease. The company also develops VAX-31 to protect against emerging strains and to help address antibiotic resistance; VAX-A1, a novel conjugate vaccine candidate to prevent disease caused by Group A Streptococcus; VAX-PG, a novel protein vaccine candidate targeting keystone pathogen responsible for periodontitis; and VAX-GI to prevent Shigella, a bacterial illness. The company was formerly known as SutroVax, Inc. and changed its name to Vaxcyte, Inc. in May 2020. Vaxcyte, Inc. was incorporated in 2013 and is headquartered in San Carlos, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time